Biomarkers Index is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
A comprehensive guide to biomarkers for neurodegenerative diseases, organized by category. Biomarkers are measurable indicators of biological processes, disease states, or therapeutic responses.
Neurodegenerative diseases are characterized by the progressive loss of neuronal function and structure. Biomarkers play a critical role in:
- Early Detection: Identifying disease before clinical symptoms appear
- Diagnosis: Distinguishing between different neurodegenerative conditions
- Disease Progression: Monitoring disease severity and rate of progression
- Therapeutic Response: Evaluating the effectiveness of treatments
- Clinical Trials: Enriching trial populations and measuring target engagement
- Amyloid: Aβ40, Aβ42/40 Ratio
- Tau: Total Tau, Tau Oligomers
- Neuroinflammation: GFAP, YKL-40, sTREM2
- Synaptic: Neurogranin, SNAP-25, SV2A
- Neurodegeneration: NfL, NSE
- Alpha-Synuclein: Total α-Syn, pSer129, Oligomers
- Neurodegeneration: NfL, β-Synuclein
- Metabolic: GCase, BDNF
- Neurodegeneration: NfL, pNfH, NSE
- Neuroinflammation: GFAP, YKL-40
- Genetic: Mutant Huntingtin Protein
- Neurodegeneration: NfL, Neurofilament
- Synaptic: Neurogranin, Synaptophysin
| Modality |
Advantages |
Limitations |
Examples |
| CSF |
High specificity for CNS |
Invasive (lumbar puncture) |
Aβ40, Tau, NfL |
| Blood |
Minimal invasiveness |
Lower sensitivity |
NfL, GFAP, p-tau |
| Imaging |
Direct visualization |
Cost, availability |
Amyloid PET, Tau PET |
| Digital |
Continuous monitoring |
Validation needed |
Gait, speech metrics |
- Aβ42/40 Ratio: Distinguishes AD from other dementias
- NfL: Generic neurodegeneration marker, helps differentiate parkinsonism
- pSer129: Supports PD/DLB diagnosis
- NfL: Predicts progression rate in MS, ALS, PD
- GFAP: Associated with cognitive decline in AD
- Tau: Correlates with disease severity
The study of Biomarkers Index has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects. EMBO Mol Med. 2018;10(12).
- Parnetti L, et al. Cerebrospinal fluid biomarkers in neurodegenerative diseases. Neurol Sci. 2019;40(7):1467-1477.
- Ashton NJ, et al. Blood biomarkers for Alzheimer's disease and related disorders. J Neurol Neurosurg Psychiatry. 2022.
- Gaetani L, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019.